^ abZhu, J; Mix, E; Winblad, B (2001 Winter). “The antidepressant and antiinflammatory effects of rolipram in the central nervous system.”. CNS drug reviews7 (4): 387–98. PMID11830756.
^Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. (1993). “Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response”. Inflammation17 (3): 333–44. doi:10.1007/BF00918994. PMID7687237.
^Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H. (1988). “Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives”. Eur Arch Psychiatry Neurol Sci238 (1): 2–6. doi:10.1007/BF00381071. PMID3063534.
^Wachtel H. (1983). “Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors”. Neuropharmacology22 (3): 267–72. doi:10.1016/0028-3908(83)90239-3. PMID6302550.
^ abSommer, N; Löschmann, PA; Northoff, GH; Weller, M; Steinbrecher, A; Steinbach, JP; Lichtenfels, R; Meyermann, R; Riethmüller, A; Fontana, A (1995 Mar). “The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.”. Nature medicine1 (3): 244–8. PMID7585041.
^Chen, TC; Wadsten, P; Su, S; Rawlinson, N; Hofman, FM; Hill, CK; Schönthal, AH (2002 May-Jun). “The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells.”. Cancer biology & therapy1 (3): 268–76. PMID12432276.
^Semmler, J; Wachtel, H; Endres, S (1993 Apr). “The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.”. International journal of immunopharmacology15 (3): 409–13. PMID8505151.
^Mendes, E; Wadsten, P; Su, S; Rawlinson, N; Hofman, FM; Hill, CK; Schönthal, AH (1975 Nov). “Immunological studies on bronchial secretion. I. Antigenic relationship between bronchial secretion and serum: bronchial secretion constituents detected in human sera.”. Acta allergologica30 (5): 259–66. PMID12432276.
^Maxwell CR, Kanes SJ, Abel T, Siegel SJ. (2004). “Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications”. Neuroscience129 (1): 101–7. doi:10.1016/j.neuroscience.2004.07.038. PMID15489033.
^Lelkes Z, Alföldi P, Erdos A, Benedek G. (1998). “Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats”. Pharmacology, Biochemistry and Behaviour60 (4): 835–9. doi:10.1016/S0091-3057(98)00038-0. PMID9700966.
^Chen RW, Williams AJ, Liao Z, Yao C, Tortella FC, Dave JR. (2007). “Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation”. Neuroscience Letters418 (2): 165–9. doi:10.1016/j.neulet.2007.03.033. PMID17398001.
^MF, Beal; Cleren C, Calingasan NY, Yang L, Klivenyi P, Lorenzl S (2005年). “Oxidative Damage in Parkinson's Disease”. U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012. 2009年11月13日閲覧。
^ Nikulina, E. (June 8, 2004). “The Phosphodiesterase Inhibitor Rolipram Delivered after a Spinal Cord Lesion Promotes Axonal Regeneration and Functional Recovery”. Proceedings of the National Academy of Sciences of the United States101 (23): 8786. doi:10.1073/pnas.0402595101. JSTOR3372336.